Jairath V, et al. - This phase 2 placebo-controlled trial of ozanimod compiled the study of derivation and externally validation of a novel index by combining clinical, endoscopic, and histological data in 179 cases of ulcerative colitis disease. Robarts histopathology index was found linked with an absence of rectal bleeding whereas the Mayo Clinic endoscopic subscore was not significantly correlated with rectal bleeding in the analysis. A developed and validated novel composite disease activity index (the UC-100 score) was detected with a good discriminative performance in early phase trials of ulcerative colitis.